1. Repositório da Universidade de Lisboa
  2. Comunidades & Colecções
  3. Instituto de Medicina Molecular João Lobo Antunes (iMM)
  4. IMM - Artigos em Revistas Internacionais
Utilize este identificador para referenciar este registo: http://hdl.handle.net/10451/50253
Registo completo
Campo DCValorIdioma
degois.publication.firstPage2032pt_PT
degois.publication.issue8pt_PT
degois.publication.lastPage2034pt_PT
degois.publication.titleAngewandte Chemie International Editionpt_PT
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/journal/15213773?tabActivePane=undefinedpt_PT
dc.contributor.authorRodrigues, Tiago-
dc.contributor.authorBernardes, Gonçalo J. L.-
dc.date.accessioned2021-12-02T15:42:53Z-
dc.date.available2021-12-02T15:42:53Z-
dc.date.issued2018-
dc.identifier.citationAngew Chem Int Ed Engl. 2018 Feb 19;57(8):2032-2034pt_PT
dc.identifier.issn1433-7851-
dc.identifier.urihttp://hdl.handle.net/10451/50253-
dc.description© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.pt_PT
dc.description.abstractLess is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.pt_PT
dc.description.sponsorshipWe thank FCT Portugal (iFCT) the EU (Marie Sklodowska-Curie ITN ProteinConjugates) and the EPSRC to G.J.L.B. T.R. is a Marie Sklodowska-Curie Fellow (Grant 743640). G.J.L.B. is a Royal Society URF and recipient of an ERC StG (TagIt).pt_PT
dc.language.isoengpt_PT
dc.publisherJohn Wiley & Sons, Inc.pt_PT
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/743640/EUpt_PT
dc.rightsopenAccesspt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectAnti-tumor agentspt_PT
dc.subjectAntibody-drug conjugatespt_PT
dc.subjectBioconjugationpt_PT
dc.subjectDrug deliverypt_PT
dc.subjectLinkerspt_PT
dc.titleDevelopment of antibody-directed therapies: quo vadis?pt_PT
dc.typearticlept_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.peerreviewedyespt_PT
degois.publication.volume57pt_PT
dc.identifier.doi10.1002/anie.201712185pt_PT
dc.identifier.eissn1521-3773-
Aparece nas colecções:IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Development_antibody.pdf631,65 kBAdobe PDFVer/Abrir
Mostrar registo em formato simples Dê a sua opinião sobre este registo.


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.